Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY: BMY )

63.82 -0.74 (-1.15%)
Official Closing Price Updated: 7:00 PM EDT, May 26, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Bristol-Myers Squibb

< Previous 1 2
...
22 23 24 25 26 27 28 29 Next >
14 Biotech Stocks To Watch Over The Next 6 Months
Biotechs are at the mercy of several make-or-break catalysts that invariably have a big impact on stocks. A case in point was the strong upside in Biogen Inc.'s (NASDAQ:... 
Via Benzinga
Which Is A Better Investment? Amgen Vs Bristol-Myers Squibb… The Winner May Surprise You
Both companies have the same yield, at right about 2.9%. They've also both been increasing their dividends for almost the same exact length of time - 12 years for Bristol-Myers Squibb versus 11 years... 
Via Talk Markets
The 2 Best Pharma Stocks to Buy on Dips
Because the COVID-19 pandemic is under control in most major economies, the hype surrounding vaccine producers is gradually tapering off. 
Via Talk Markets
Exposures COVID-19
10 Health Care Stocks Showing Unusual Options Activity In Today's Session
This unusual options alert can help traders track potentially big trading opportunities. Traders often look for circumstances when the market estimation of an option diverges away... 
Via Benzinga
Healthcare Portfolio Playbook: Time To Rebalance With MedTech
As we look to re-balance our portfolio in the near-term, investors should consider adding Medtech as we have suggested in the past. Though, more recently, we have also focused on large-cap... 
Via Talk Markets
Bristol Myers Onureg Scores European Approval As Maintenance Therapy For Acute Myeloid Leukemia
The European Commission has granted full marketing authorization to Bristol Myers Squibb & Co's (NYSE: BMY) Onureg (azacitidine tablets) The approval... 
Via Benzinga
The Daily Biotech Pulse: Orphazyme Falters At FDA, Athira's CEO Placed On Temporary Leave, 5 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 17) 10x Genomics, Inc. (NASDAQ... 
Via Benzinga
Exposures Product Safety
Bristol Myers Inks Licensing Pact For Eisai's Folate Receptor ADC Drug, Lays Out Over $3B For Rights
Eisai Co Ltd (OTC: ESALY) and Bristol-Myers Squibb Co (NYSE: BMY) have entered into an exclusive global strategic collaboration agreement for the co-... 
Via Benzinga
Why Kindred Biosciences, Aprea, Catabasis And Inhibikase Are Moving Today
Kindred Biosciences, Inc. (NASDAQ: KIN), Aprea Therapeutics, Inc. (NASDAQ: APRE), Catabasis Pharmaceuticals, Inc. (NASDAQ: CATB) and Inhibikase Therapeutics, Inc. (NASDAQ: IKT)... 
Via Benzinga
IPO Preview: WalkMe, Atai Life Sciences Highlight Week Of Many Offerings
This week’s IPO lineup could feature a double digit number of companies hitting the public. Here is a look at some of the largest and most high profile companies going... 
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
Johnson & Johnson Building Case With New Patient Survival Data For Darzalex In Multiple Myeloma
Janssen Pharmaceutical, a unit of Johnson & Johnson (NYSE: JNJ), announced overall survival (OS) results from the Phase 3 MAIA study evaluating the... 
Via Benzinga
Investing Vs. Trading - Week In Review
I personally view anything over 30X as overvalued based on historical data. Note that we are near or over 40X and valuation levels near the top of the dot-com era. 
Via Talk Markets
How Big Is Bristol Myers Squibb's Latest FDA Approval?
It's an important win for a drug gained in the Celgene acquisition to reach blockbuster status. 
Via The Motley Fool
Exposures Product Safety
Unheeding Markets
Today oil prices rose over $70. 
Via Talk Markets
The Daily Biotech Pulse: US To Procure 500M Pfizer-BioNTech Vaccine Doses For Donation, Verona Out-Licenses COPD Drug, Nautilus Lists Through SPAC Deal
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 9) Aethlon Medical, Inc. (... 
Via Benzinga
Wednesday News And Catch-Up
Today the US market resumed its attempt to hit a new record for the S&P 500 and Nasdaq, but not the DJIA. 
Via Talk Markets
Topics Stocks
Exposures US Equities
3 Top Pharma Stocks to Buy This Month
In 2020, pharmaceutical stocks came to the forefront as healthcare companies were searching for treatments for COVID-19. 
Via Talk Markets
3 Buffett Stocks to Buy Hand Over Fist in June
The Oracle of Omaha has a knack for owning great companies that can make investors rich. 
Via The Motley Fool
2 Blue Chips to Buy Now for a Bear Market
If it's steadiness you're after, these two healthcare giants have shown they can perform during a pandemic and beyond. 
Via The Motley Fool
FDA surprise
The big news out of China is that its import purchases of copper and iron sagged last month because its export markets are far less strong than earlier this year. 
Via Talk Markets
Exposures Product Safety
This Company Is More Investable Than It’s Ever Been And Is Rated A “Buy”
Bristol-Myers Squibb Co. is a high-quality biopharmaceutical company with one of the best-selling products in its entire industry. Huge long-term demographic tailwinds blow its way, further bolstering... 
Via Talk Markets
Here's What Crushed Exelixis' Earnings
R&D spending is hurting earnings, but long-term investors shouldn't be worried. 
Via The Motley Fool
Is Editas the Best Genetics Stock to Buy?
There are some big opportunities in the gene editing space. 
Via The Motley Fool
The Week Ahead In Biotech: Biogen, Alexion And Vertex FDA Decisions, Multiple Conference Presentations On The Deck
Biopharma stocks advanced in the truncated week ended June 4 amid the broader market strength. The American Society for Clinical Oncology meeting got underway during the week,... 
Via Benzinga
Exposures Product Safety
A Better Switch
Today the US market decided to rise because President Biden is pondering not linking his infrastructure project to a corporate tax increase. 
Via Talk Markets
The Daily Biotech Pulse: Merck, AstraZeneca, Novartis Among Early Presenters At ASCO, Sanofi Strikes Breast Cancer Study Pact
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 3) BioCryst Pharmaceuticals,... 
Via Benzinga
Bristol Myers Touts Opdivo Win in Esophageal Cancer, But Yervoy-Opdivo Combo Comes with Caution
Bristol Myers Squibb & Co (NYSE: BMY) announced results from the Phase 3 CheckMate-648 trial, which had two Opdivo-based treatment combinations — Opdivo... 
Via Benzinga
Bristol Myers Faces $6.4B Lawsuit Over Delayed Approval of Breyanzi Non-Hodgkin Lymphoma Drug: Reuters
Bristol Myers Squibb Co (NYSE: BMY) was sued for $6.4 billion for allegedly delaying approval for Breyanzi cancer drug to avoid payments to shareholders of the... 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
The Daily Biotech Pulse: Merck Completes Organon Spin-Off, Auris Repositions As RNA Therapeutic Company With Trasir Purchase, Replimune's Readout
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 2) BioCryst Pharmaceuticals,... 
Via Benzinga
Diversifying to Conquer: Fortress Biotech (FBIO) Partnering Expansion Driving Progress in Cancer Immunotherapy and Rare Disease Therapeutics
The following article is sponsored by the clinical communications unit of Redington, Inc. The information contained in this article in no way represents investment advice or... 
Via Benzinga
< Previous 1 2
...
22 23 24 25 26 27 28 29 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.